5. Conclusion
CLD, bleeding
THROMBOCYTOPENIA, BLEEDING, CLD
The results of this real-world study indicate that avatrombopag is effective in a patient population with CLD of diverse etiologies and severity. Importantly, avatrombopag was well tolerated and effective in increasing platelet counts, allowing procedures to be performed with greater confidence. The limited data presented in this study also suggest that avatrombopag is suitable for repeated use and can be used to prevent periprocedural bleeding in surgical interventions not previously studied. In a real-world setting in patients with CLD and thrombocytopenia, treatment with avatrombopag consistently increased platelet counts to nearly double the baseline platelet count by the day of the procedure and reduced the need for platelet transfusions.